CD19 and acute lymphoblastic leukemia: Since 2017, six different CAR-T cell therapies have been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), including 4 anti-CD19 CAR-Ts and 2 anti-BCMA CAR-Ts for the treatment of B-ALL, B-NHL, and MM (174).